Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

NCT04875806 is registered in ClinicalTrials.gov with NextCure, Inc. as lead sponsor.

NCT NCT04875806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04875806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
NextCure, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2021
Completion date
January 30, 2024
Enrollment
40 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, breast cancer, non-small cell lung cancer, ovarian cancer